WO2018233619A1 - Procédé d'établissement d'un modèle de profil de glycome de glycoprotéine sérique d'une insuffisance hépatique - Google Patents

Procédé d'établissement d'un modèle de profil de glycome de glycoprotéine sérique d'une insuffisance hépatique Download PDF

Info

Publication number
WO2018233619A1
WO2018233619A1 PCT/CN2018/091922 CN2018091922W WO2018233619A1 WO 2018233619 A1 WO2018233619 A1 WO 2018233619A1 CN 2018091922 W CN2018091922 W CN 2018091922W WO 2018233619 A1 WO2018233619 A1 WO 2018233619A1
Authority
WO
WIPO (PCT)
Prior art keywords
liver failure
reagent
serum
peak
profile model
Prior art date
Application number
PCT/CN2018/091922
Other languages
English (en)
Chinese (zh)
Inventor
陈翠英
Original Assignee
江苏先思达生物科技有限公司
陈翠英
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 江苏先思达生物科技有限公司, 陈翠英 filed Critical 江苏先思达生物科技有限公司
Publication of WO2018233619A1 publication Critical patent/WO2018233619A1/fr

Links

Images

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
    • G01N30/02—Column chromatography
    • G01N30/86—Signal analysis
    • G01N30/8675—Evaluation, i.e. decoding of the signal into analytical information
    • G01N30/8686—Fingerprinting, e.g. without prior knowledge of the sample components
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
    • G01N30/02—Column chromatography

Definitions

  • the invention belongs to the technical field of biomedicine and relates to a method for establishing a serum glycoprotein glycoprotein pattern model of liver failure.
  • Liver failure is a serious liver damage caused by a variety of factors, leading to serious disorders or decompensation of the liver's own synthesis, detoxification, excretion and biotransformation. Clinically, there are coagulation disorders, jaundice, A group of syndromes characterized by hepatic encephalopathy and dehydration have extremely high mortality. Liver failure in Europe and the United States is mainly caused by drugs. The cause of liver failure in China is mainly caused by hepatitis virus infection (mainly hepatitis B virus HBV).
  • hepatitis virus infection mainly hepatitis B virus HBV
  • Hepatic failure may occur in HBV serological markers positive infections, a large number of viral replication leads to hepatocyte nutrient depletion, immune paralysis is a prerequisite for liver injury, followed by liver failure caused by drugs and hepatotoxic substances (such as ethanol, chemicals, etc.) .
  • drugs and hepatotoxic substances such as ethanol, chemicals, etc.
  • the medical treatment of liver failure still lacks special effects drugs and means. In principle, it emphasizes early diagnosis and early treatment, and adopts corresponding etiological treatment measures and comprehensive treatment measures for different causes, and actively prevents various complications. After the diagnosis of liver failure is clear, the condition assessment and intensive care should be performed.
  • Histopathological examination has important value in the diagnosis, classification and prognosis of liver failure.
  • hepatic puncture has certain risks, which may cause complications such as bleeding and infection.
  • There is sampling error because the liver biopsy center only accounts for 1/200,000-150,000 of the liver, which can not reflect the whole liver lesion; the patient's dependence is poor, and the single pathological examination results can not reflect the whole degree of liver failure.
  • the clinical diagnosis of liver failure needs to be determined based on comprehensive analysis such as medical history, clinical manifestations and auxiliary examination. Patients with liver failure usually have clinical symptoms, such as jaundice, fatigue, bloating, etc., and further examination is needed to confirm the diagnosis.
  • Hepatitis virus standard test to understand the specific virus type causing liver failure, such as HBV or HCV-positive, further quantitative detection of virus to assess the degree of viral replication
  • complete blood cell analysis including white blood cells, hemoglobin, platelets, white blood cell classification, etc., to understand whether there is hypersplenism and infection
  • urine routine including Specific gravity, pH value, urobilinogen, urinary bilirubin, etc., indirectly judge the type of jaundice, preliminary judgment of the body's metabolic status
  • liver function including ALT, AST, TBIL, ALB, CHE, CHO, PALB, etc.
  • the degree of liver damage and liver combined reserve capacity (5) ultrasound or CT, nuclear magnetic, evaluation of liver size, degree of injury and blood vessels, bile duct diameter, and exclusion of malignant obstructive lesions.
  • ultrasound or CT nuclear magnetic
  • evaluation of liver size degree of injury and blood vessels
  • bile duct diameter degree of injury and blood vessels
  • exclusion of malignant obstructive lesions e.g., obstructive lesions.
  • electronic gastroscopy or gastrointestinal angiography is needed to understand varicose veins and gastric mucosa.
  • the above diagnostic methods have their own limitations, and it is necessary to use a variety of diagnostic methods to confirm the diagnosis based on the doctor's clinical experience. It takes a long time, the examination cost is high, and it is not convenient to carry out the screening of liver failure, so it is urgent to explore for assistance.
  • a new noninvasive indicator for the diagnosis of liver failure with high sensitivity and specificity.
  • Glycoproteins are a class of binding proteins formed by post-translational modification of proteins, ie, glycosylation. Glycosylation of proteins is one of the most common post-translational modifications of proteins. It is the process of transferring sugars to specific amino acid residues on proteins and proteins to form glycosidic bonds under the action of glycosyltransferases. Most glycoproteins are secreted proteins that are widely found in cell membranes, interstitial cells, plasma, and mucus. Glycoproteins have a variety of biological functions. Because of the importance of sugar chains in glycoproteins to maintain the biological functions of the body, changes in sugar chains help to elucidate the molecular mechanisms of abnormal biological behavior such as inflammation, invasion and metastasis of surrounding cells by surrounding cells. At present, changes in N-glycans have been found in a variety of tumors.
  • the structure of the sugar chain is very complicated and has microscopic heterogeneity.
  • the analysis methods of the sugar chain structure mainly include: (1) High performance liquid chromatography (HPLC): the method has high resolution, high detection speed and high repeatability, high-performance liquid phase. Columns can be used repeatedly, but the column efficiency will decrease with the increase in the number of uses, and the mobile phase is toxic. Equipment operation requires highly trained professionals, and the equipment is relatively expensive, and the solvent needs to be strictly purified.
  • Mass spectrometry has the advantages of high sensitivity, various structural information and suitable for analysis of mixtures, but the mass spectrometer is precise, the equipment operation is complicated, and the mass spectrometer is expensive, which is not suitable for popularization and promotion in clinical practice;
  • Capillary electrophoresis Capillary electrophoresis has low cost, high column efficiency, high sensitivity, high speed, low injection volume, and simple operation, but the repeatability is not high and the stability is not as good as HPLC.
  • G-Test is a capillary micro-electrophoresis technique (DSA-FACE) based on DNA sequencer.
  • DSA-FACE capillary micro-electrophoresis technique
  • the N-glycan of glycoprotein in serum samples is fluorescently labeled and separated by capillary microelectrophoresis.
  • the content of the N-oligosaccharide chain obtained by measuring the fluorescence signal is a fingerprint (referred to as G-Test map).
  • the detection technology has the advantages of high sensitivity, simple operation, trace (2 ⁇ l serum), high reproducibility, good stability, high-throughput (96-well plate) and other sugar chain analysis techniques, which is suitable for general laboratory. It is expected to be used for clinical promotion.
  • the present invention provides a method for establishing a serum glycoprotein glycoprotein map model for liver failure.
  • NA2 two antennas, bigalacto, and biantennary
  • the method for establishing a serum glycoprotein glycoform map model of liver failure is as follows:
  • Step 1 Collect serum from patients with liver failure and normal controls
  • Step 2 preparing a solution containing 5% SDS (sodium dodecyl sulfate) at a concentration of 10 mM, a pH of 8.3, NH 4 HCO 3 as reagent A, and reagent B from 2.2 U/ ⁇ L of PNGaseF and 3.33% of NP-40.
  • SDS sodium dodecyl sulfate
  • reagent B 2.2 U/ ⁇ L of PNGaseF and 3.33% of NP-40.
  • reagent C was prepared by mixing 20 mM APTS (8-aminoindole-1,3,6-trisulphonic acid) and 1 M NaCNBH 3 in equal volumes.
  • Reagent D consisted of 100 mM NH 4 AC, 2 mU/ ⁇ L of sialidase and hydrogen peroxide are mixed in a volume ratio of 5:1:14;
  • Step 3 preparation of oligosaccharide chain: adding half volume of reagent A to the diluted serum, denaturation at 95 ° C for 5 min, then adding reagent B with the same volume of serum, reacting at 37 ° C for 3 h and then drying;
  • Step 4 labeling of the oligosaccharide chain: adding the reagent C of the same volume as the reagent A in the liquid of the step 3, reacting at 65 ° C for 3 h for fluorescent labeling, and then adding water to terminate the labeling reaction;
  • Step 5 desialic acid treatment: take an equal volume of step 4 fluorescently labeled liquid and reagent D at 45 ° C for 3 h, then add water to terminate the reaction;
  • Step 6 Oligosaccharide chain separation analysis: the liquid after the sialic acid treatment in step 5 is taken, and the fragment analysis is performed by a DNA sequencer to obtain a sugar group map;
  • step 7 the obtained sugar group map is subjected to peak quantification, and the peak height value of each peak is divided by the sum of the heights of all the peaks, and the relative content of each peak is quantitatively calculated, and then the quantified liver failure group and The peak value of NA2 in the sugar group map of the normal control group was compared and statistically analyzed.
  • step 1 the serum is inactivated.
  • step 4 the fluorescent labeling time of the serum sample is 3h to ensure the success rate of the label. Under the general experimental conditions, the test requirement can be met within 2.5 hours.
  • step 5 the reaction time for removing the terminal sialic acid is 3 hours, and in order to ensure sufficient contact reaction of the enzyme, the reaction can be made more complete by extending to 4 hours.
  • step 7 the cut-off value of the relative content of NA2 is 35.6.
  • the present invention has the following advantages:
  • the method of the invention adopts the G-Test detection method with high sensitivity, simple operation, only a small amount of sample, high repeatability, good stability and high throughput, and establishes a sugar group map with significant difference between liver failure patients and normal control personnel.
  • the model was screened for a significant difference in NA2 between the liver failure group and the normal control group.
  • the degree of liver failure of the test subject can be detected by the peak of the single peak NA2 in the map model established by the method in the glycoform map of the serum of the test subject, compared with the prior art, With higher specificity and accuracy, the sensitivity and specificity for detection of liver failure reached 100.0% and 97.6%, respectively.
  • the glycoform map model constructed based on the method of the present invention can enable many patients with chronic hepatitis and liver failure to undergo routine and non-invasive testing, and help doctors and patients to timely monitor the occurrence of failure and progression of the disease, and is expected to be promoted in clinical use.
  • Figure 1 is a graph of serum glycoprotein glycoforms in the normal control group (A) and the liver failure group (B).
  • Figure 2 is a graph showing the ROC curve for the differential diagnosis of liver failure by NA2.
  • Serum samples from 92 patients with liver failure and control group were treated by G-Test. Among them, 42 patients with liver failure and 50 patients without normal hepatitis B virus. The glycan profiles obtained from the G-Test detection technique were statistically analyzed.
  • Reagent A SDS was dissolved in 10 mM NH 4 HCO 3 to prepare a NH 4 HCO 3 solution containing 5% SDS and a pH of 8.3.
  • Reagent B 2.2 U/ ⁇ L of PNGaseF and 3.33% of NP-40 were mixed at a volume ratio of 1:20;
  • Reagent C mixing equal volumes of 20 mM APTS and 1 M NaCNBH 3 ;
  • Reagent D 100 mM NH4AC, sialidase (2 mU/ ⁇ L) and hydrogen peroxide were mixed at a volume ratio of 5:1:14.
  • Step 1 Preparation of oligosaccharide chain: 2 ⁇ L of reagent A was added to 4 ⁇ L of diluted serum, and denatured at 95 ° C for 5 minutes, then an equivalent volume (4 ⁇ L) of reagent B was added, and reacted at 37 ° C for 3 hours and then dried;
  • Step 2 labeling of the oligosaccharide chain: adding 2 ⁇ L of reagent C to the liquid of step 1, reacting at 65 ° C for 3 hours for fluorescent labeling, and then adding 200 ⁇ L of water to terminate the labeling reaction;
  • Step 3 post-labeling treatment: take 2 ⁇ L of fluorescently labeled step 2 liquid, add 2 ⁇ L of reagent D, react at 45 ° C for 3 hours, then add 200 ⁇ L of water to terminate the reaction;
  • Step 4 Oligosaccharide chain separation analysis: 10 ⁇ L of the liquid after the step 3 reaction was taken, and the N-oligosaccharide chain was separated by an ABI 3500dx sequencer to obtain a sugar group map.
  • step 5 the obtained sugar group map is subjected to peak quantification, and the relative content of each peak is quantitatively calculated by dividing the peak height value of each peak by the sum of the heights of all the peaks, and statistical analysis is performed.
  • the glycan profile of human serum probably shows nearly 9 N-oligosaccharide chain peaks.
  • the oligosaccharide chains exhibit different mobility due to different molecular sizes, that is, they are expressed on the glycan map.
  • the different peaks represent different oligosaccharide chains, and the measured peak height represents the relative concentration of oligosaccharide chains, A is the normal control group and B is the liver failure group.
  • the relative content of NA2 in the normal control group was 47%, and the relative content of NA2 in the liver failure group was 35%. It can be seen that the oligosaccharide content of the unimodal NA2 in the liver failure group and the normal control group was significant. gap.

Landscapes

  • Analytical Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pathology (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • General Physics & Mathematics (AREA)
  • Engineering & Computer Science (AREA)
  • Library & Information Science (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

L'invention concerne un procédé d'établissement d'un modèle de profil de glycome de glycoprotéine sérique de l'insuffisance hépatique. Le procédé utilise un procédé de détection de Test G pour détecter un profil de glycome de glycoprotéine sérique, établit un modèle de profil de glycome, avec des patients atteints d'insuffisance hépatique et des contrôles normaux ayant une différence significative entre eux, et effectue un dépistage de NA2 dont l'expression est significativement différente entre le groupe atteint d'insuffisance hépatique et le groupe de contrôle normal. Sur la base du modèle de profil de N-glycome construit, la sensibilité de détection et la spécificité pour une insuffisance hépatique atteignent 100,0 % et 97,6 %, respectivement. Dans des applications subséquentes, le degré d'insuffisance hépatique de personnes à tester peut être détecté par comparaison de la valeur de pic du singulet NA2 dans le profil N-glycome du sérum des personnes à tester avec celle de celui-ci dans le modèle de profil établi. Le procédé peut permettre à de nombreux patients souffrant d'une insuffisance hépatique de subir une détection de routine, non invasive, aide les médecins et les patients à surveiller l'occurrence et la progression de la maladie de l'insuffisance hépatique d'une manière opportune, et devrait être généralisé et utilisé cliniquement.
PCT/CN2018/091922 2017-06-20 2018-06-20 Procédé d'établissement d'un modèle de profil de glycome de glycoprotéine sérique d'une insuffisance hépatique WO2018233619A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN201710469179.9 2017-06-20
CN201710469179.9A CN107894483A (zh) 2017-06-20 2017-06-20 肝衰竭的血清糖蛋白n‑糖组图谱模型的建立方法

Publications (1)

Publication Number Publication Date
WO2018233619A1 true WO2018233619A1 (fr) 2018-12-27

Family

ID=61803123

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CN2018/091922 WO2018233619A1 (fr) 2017-06-20 2018-06-20 Procédé d'établissement d'un modèle de profil de glycome de glycoprotéine sérique d'une insuffisance hépatique

Country Status (2)

Country Link
CN (1) CN107894483A (fr)
WO (1) WO2018233619A1 (fr)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107894483A (zh) * 2017-06-20 2018-04-10 江苏先思达生物科技有限公司 肝衰竭的血清糖蛋白n‑糖组图谱模型的建立方法
CN109100410B (zh) * 2017-06-20 2020-11-13 江苏先思达生物科技有限公司 肝硬化的血清糖蛋白n-糖组图谱模型的建立方法
CN109100507A (zh) * 2017-06-20 2018-12-28 江苏先思达生物科技有限公司 慢性肝炎肝损伤的血清糖蛋白n-糖组图谱模型的建立方法
CN114032284A (zh) * 2021-09-15 2022-02-11 陈翠英 一种食管癌检测试剂及其在食管癌检测中的应用
CN114032282A (zh) * 2021-09-15 2022-02-11 陈翠英 一种前列腺癌检测试剂及其在前列腺癌检测中的应用
CN114032283A (zh) * 2021-09-15 2022-02-11 陈翠英 一种肠癌检测试剂及其在肠癌检测中的应用
CN114058673A (zh) * 2021-09-15 2022-02-18 江苏先思达生物科技有限公司 一种脂肪肝检测试剂及其在脂肪肝检测中的应用
CN114034752A (zh) * 2021-09-15 2022-02-11 先思达（南京）生物科技有限公司 一种肝衰竭检测试剂及其在肝衰竭检测中的应用

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100151499A1 (en) * 2007-04-16 2010-06-17 Momenta Pharmaceuticals, Inc. Proteolytic release of glycans
CN102492680A (zh) * 2011-12-30 2012-06-13 河南大学 与血清中刀豆素A特异结合的组织蛋白酶D酶原ConA-pCD及应用
CN102565318A (zh) * 2012-01-11 2012-07-11 陈翠英 一种肝癌监测、分期以及预后风险评估的试剂及其方法
CN104807998A (zh) * 2015-05-12 2015-07-29 先思达（南京）生物科技有限公司 一种早期肝癌诊断试剂盒及其使用方法
CN107894483A (zh) * 2017-06-20 2018-04-10 江苏先思达生物科技有限公司 肝衰竭的血清糖蛋白n‑糖组图谱模型的建立方法

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101576495B (zh) * 2009-06-09 2011-11-09 中国人民解放军第二军医大学 一种检测血清N糖log(P9/P4)的方法、检测系统及其应用
CN102707062A (zh) * 2011-03-27 2012-10-03 上海交通大学附属第一人民医院 检测慢性乙肝肝纤维化血清n-糖组峰标记的方法及其用途

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100151499A1 (en) * 2007-04-16 2010-06-17 Momenta Pharmaceuticals, Inc. Proteolytic release of glycans
CN102492680A (zh) * 2011-12-30 2012-06-13 河南大学 与血清中刀豆素A特异结合的组织蛋白酶D酶原ConA-pCD及应用
CN102565318A (zh) * 2012-01-11 2012-07-11 陈翠英 一种肝癌监测、分期以及预后风险评估的试剂及其方法
CN104807998A (zh) * 2015-05-12 2015-07-29 先思达（南京）生物科技有限公司 一种早期肝癌诊断试剂盒及其使用方法
CN107894483A (zh) * 2017-06-20 2018-04-10 江苏先思达生物科技有限公司 肝衰竭的血清糖蛋白n‑糖组图谱模型的建立方法

Also Published As

Publication number Publication date
CN107894483A (zh) 2018-04-10

Similar Documents

Publication Publication Date Title
WO2018233619A1 (fr) Procédé d'établissement d'un modèle de profil de glycome de glycoprotéine sérique d'une insuffisance hépatique
WO2018233617A1 (fr) Procédé d'établissement d'un modèle de profil de glycome de glycoprotéines sériques d'une hépatite chronique et d'une atteinte hépatique
WO2023040868A1 (fr) Réactif de détection de l'insuffisance hépatique et son utilisation dans la détection de l'insuffisance hépatique
CN109100410B (zh) 肝硬化的血清糖蛋白n-糖组图谱模型的建立方法
WO2023040912A1 (fr) Réactif de détection du cancer de la prostate et son utilisation dans la détection du cancer de la prostate
WO2023040910A1 (fr) Réactif de détection de l'hépatite c et du cancer hépatique, et son application dans la détection de l'hépatite c et du cancer hépatique
JP2017502307A (ja) 唾液の糖タンパク質糖鎖に基づいて肝疾患を識別するレクチンチップ及びその使用
CN107505295A (zh) 一种肝癌监测试剂盒及其使用方法
WO2023040908A1 (fr) Réactif de détection de la stéatose hépatique et son utilisation dans la détection de la stéatose hépatique
WO2023040911A1 (fr) Réactif de détection du carcinome du rectum et son application dans la détection du carcinome du rectum
WO2023040909A1 (fr) Réactif de détection de carcinome oesophagien et son application dans la détection de carcinome oesophagien
WO2024183386A1 (fr) Réactif de détection à base de chaîne d'oligosaccharide pour détecter un cancer de la prostate, procédé de préparation et utilisation
WO2024183385A1 (fr) Réactif de détection à base de chaîne d'oligosaccharides pour détecter un cancer intestinal, procédé de préparation, et utilisation
CN118091135B (zh) 一种生物标记物用于制备表征甲状腺乳头状癌产品的用途及其筛选方法
CN109613127A (zh) 一种鉴定痛风性关节炎生物标记物的方法及检测试剂盒
CN109682975B (zh) 一种乙型肝炎检测试剂及其在乙型肝炎检测中的应用
CN116183921A (zh) 一种基于寡糖链检测胰腺癌的检测试剂、制备方法及应用
CN114136932A (zh) 一种子宫内膜样腺癌检测试剂及其在子宫内膜样腺癌检测中的应用
CN104792900B (zh) 一种尿液中急性肾损伤生物标志物质谱相对定量方法
Wang et al. Serum N-Glycan Markers for Diagnosing Significant Liver Fibrosis and Cirrhosis in Chronic Hepatitis B Patients with Normal Alanine Aminotransferase Levels
CN109212101A (zh) 一种鉴定哮喘生物标记物的方法及其检测试剂盒
CN115825202A (zh) 一种基于寡糖链检测慢性乙型肝炎患者肝纤维化的检测试剂、制备方法及应用
CN109406671A (zh) 一种鉴定类风湿性关节炎生物标记物的方法及其试剂盒
CN115980359A (zh) 一种基于寡糖链检测乙肝肝癌的检测试剂、制备方法及应用
WO2022247939A1 (fr) Dispositif de diagnostic du cancer du foie

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 18820329

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 18820329

Country of ref document: EP

Kind code of ref document: A1